Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

IBEX Technologies Inc

Healthcare CA IBT

1.44CAD
0.00(0%)

Last update at 2024-04-10T13:30:00Z

Day Range

1.441.44
LowHigh

52 Week Range

0.741.20
LowHigh

Fundamentals

  • Previous Close 1.44
  • Market Cap26.23M
  • Volume0
  • P/E Ratio7.13
  • Dividend Yield-%
  • EBITDA1.72M
  • Revenue TTM7.80M
  • Revenue Per Share TTM0.30
  • Gross Profit TTM 5.36M
  • Diluted EPS TTM0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Income before tax 2.02M 2.39M 0.97M 1.28M -1.32787M
Minority interest - - - - -
Net income 3.89M 1.67M 0.76M 0.97M -1.26768M
Selling general administrative 3.05M 2.74M 2.04M 2.10M 2.09M
Selling and marketing expenses - - - - -
Gross profit 5.20M 5.36M 3.03M 2.97M 1.36M
Reconciled depreciation 0.44M 0.37M 0.39M 0.17M 0.28M
Ebit - 2.27M 0.86M 0.74M -1.03386M
Ebitda - 2.83M 1.40M 1.54M -0.98398M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 1.85M 2.27M 0.86M 0.87M -1.03386M
Other operating expenses - - - - -
Interest expense 0.10M 0.08M 0.05M 0.08M 0.06M
Tax provision -1.87580M 0.71M 0.20M 0.32M -0.06019M
Interest income 0.36M 0.05M 0.00722M 0.03M 0.05M
Net interest income 0.26M -0.02971M -0.03943M -0.05422M -0.01546M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.71M 0.20M 0.32M -0.06019M
Total revenue 7.49M 7.89M 5.31M 5.21M 4.31M
Total operating expenses 5.64M 5.62M 4.45M 4.34M 5.34M
Cost of revenue 2.29M 2.53M 2.27M 2.24M 2.95M
Total other income expense net -0.09225M 0.15M 0.15M 0.47M -0.27855M
Discontinued operations - - - - -
Net income from continuing ops 3.89M 1.67M 0.76M 0.97M -1.26768M
Net income applicable to common shares - 1.67M 0.76M 0.97M -1.26768M
Preferred stock and other adjustments - - - - -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Total assets 16.83M 12.97M 9.46M 8.59M 8.39M
Intangible assets 0.04M - 0.00169M 0.01M 0.02M
Earning assets - - - - -
Other current assets - - - 0.13M -
Total liab 3.22M 3.23M 1.56M 1.47M 1.81M
Total stockholder equity 13.61M 9.75M 7.90M 7.12M 6.57M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - 52.68M 52.68M 52.67M 52.67M
Capital stock 52.54M 52.68M 52.68M 52.67M 52.67M
Retained earnings -40.01731M -43.91092M -45.58532M -46.34682M -47.31251M
Other liab - - - - -
Good will - - - - -
Other assets - 1.25M 1.92M 2.13M 2.44M
Cash 8.55M 7.64M 4.43M 3.71M 2.58M
Cash and equivalents - - - - -
Total current liabilities 1.80M 1.75M 1.10M 1.11M 0.88M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - 0.06M
Short long term debt - - - - 0.06M
Short long term debt total - - - - -
Other stockholder equity - - - - 0.50M
Property plant equipment - 2.67M 2.34M 1.54M 2.21M
Total current assets 10.23M 9.03M 5.83M 4.91M 3.71M
Long term investments - - - - -
Net tangible assets - 9.75M 7.90M 7.11M 6.55M
Short term investments - - - - -
Net receivables 0.90M 0.99M 0.95M 0.75M 0.90M
Long term debt - - - - 0.94M
Inventory 0.17M 0.23M 0.32M 0.23M 0.15M
Accounts payable 1.59M 1.58M 0.94M 0.94M 0.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 4.67M
Deferred long term asset charges - - - - -
Non current assets total 6.60M 3.92M 3.63M 3.68M 4.67M
Capital lease obligations 1.64M 1.62M 0.62M 0.53M -
Long term debt total - - - - -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Investments -1.00720M -0.14484M -0.27117M 0.95M -0.05316M
Change to liabilities - 0.63M -0.00299M 0.12M 0.20M
Total cashflows from investing activities - -0.14484M -0.27117M 0.95M -0.05316M
Net borrowings - -0.22879M -0.21314M -1.19722M -0.05379M
Total cash from financing activities -0.33392M -0.22879M -0.20914M -1.19722M -0.05379M
Change to operating activities - -0.04444M -0.02189M -0.01611M 0.00035M
Net income 3.89M 1.67M 0.76M 0.97M -1.26768M
Change in cash 0.91M 3.21M 0.73M 1.13M -0.56051M
Begin period cash flow 7.64M 4.43M 3.71M 2.58M 3.14M
End period cash flow 8.55M 7.64M 4.43M 3.71M 2.58M
Total cash from operating activities 2.25M 3.58M 1.21M 1.37M -0.45356M
Issuance of capital stock - - - - -
Depreciation 0.44M 0.37M 0.38M 0.39M 0.27M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.06M 0.09M -0.08594M -0.08680M 0.20M
Change to account receivables - -0.03664M -0.07773M 0.03M -0.19328M
Sale purchase of stock -0.04258M - - - -
Other cashflows from financing activities - - - - -
Change to netincome - 0.89M 0.25M -0.03917M 0.32M
Capital expenditures 1.01M 0.14M 0.27M 0.10M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.28643M 0.65M -0.18854M 0.04M 0.21M
Stock based compensation 0.00894M 0.17M 0.02M 0.08M 0.04M
Other non cash items 0.07M 0.05M 0.03M -0.47227M -
Free cash flow 1.24M 3.44M 0.94M 1.27M -0.51930M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IBT
IBEX Technologies Inc		 - -% 1.44 7.13 - 3.36 1.83 2.45 7.03
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

IBEX Technologies Inc

5485 Rue Pare, Montreal, QC, Canada, H4P 1P7

Key Executives

Name Title Year Born
Mr. Paul Baehr Pres, CEO & Chairman 1943
Belinda Franco C.A., CPA CFO, VP of Fin. & Admin. and Sec. NA
Mahendra Kumar Pallapothu VP of Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions